Department of Molecular and Cellular Immunology, Shinshu University Graduate School of Medicine, Nagano, Japan
Department of Medical Laboratory, Shinshu University Hospital, Nagano, Japan.
Anticancer Res. 2020 Mar;40(3):1255-1265. doi: 10.21873/anticanres.14067.
BACKGROUND/AIM: Uterine leiomyosarcoma (Ut-LMS) is a refractory tumor that repeatedly recurs with hematogenous metastasis, which may be due to the presence of drug-resistant tumor stem cells. Its treatment is limited to surgical procedures. We previously reported that Ut-LMS spontaneously developed in mice deficient in the proteasome component low-molecular mass polypeptide 2 (LMP2). We showed that LMP2 expression was significantly attenuated specifically in human Ut-LMS. The aim of this study was to investigate the role of LMP2 in hematogenous metastasis using xenograft models with tumor stem-like cells.
We isolated tumor stem-like cells from LMP2-negative primary human Ut-LMS cells established from a human Ut-LMS tissue using the side population (SP) procedure. These cells were used to develop xenograft models with tumor stem-like cells.
Human Ut-LMS stem-like cells showed stronger hematogenous metastatic potential than normal Ut-LMS cells. Tumor stem-like cells also had the potential to differentiate into vascular endothelial cells through VEGF-A signaling.
These results reflect frequent hematogenous metastasis by human Ut-LMS in clinical settings, and may lead to the development of treatments that inhibit hematogenous metastasis in Ut-LMS.
背景/目的:子宫平滑肌肉瘤(Ut-LMS)是一种难治性肿瘤,会反复出现血行转移,这可能是由于存在耐药性肿瘤干细胞。其治疗仅限于手术。我们之前报道过,在缺乏蛋白酶体成分低分子量多肽 2(LMP2)的小鼠中,Ut-LMS 会自发发展。我们表明,LMP2 的表达在人 Ut-LMS 中特异性显著减弱。本研究旨在使用具有肿瘤干细胞样细胞的异种移植模型来研究 LMP2 在血行转移中的作用。
我们使用侧群(SP)程序从源自人 Ut-LMS 组织的 LMP2 阴性原发性人 Ut-LMS 细胞中分离出肿瘤干细胞样细胞。这些细胞用于开发具有肿瘤干细胞样细胞的异种移植模型。
人 Ut-LMS 干细胞样细胞比正常 Ut-LMS 细胞具有更强的血行转移潜力。肿瘤干细胞样细胞还具有通过 VEGF-A 信号转导分化为血管内皮细胞的潜力。
这些结果反映了人 Ut-LMS 在临床环境中经常发生血行转移,并可能导致开发抑制 Ut-LMS 血行转移的治疗方法。